Applied Therapeutics CEO Shendelman Steps Down

Dow Jones

2024-12-20

By Paul Ziobro

Applied Therapeutics Chief Executive Shoshana Shendelman is stepping down from the biopharmaceutical company, which named finance chief Les Funtleyder as interim CEO.

Applied Therapeutics also brought in industry veteran John Johnson as executive chairman. Johnson, age 66, has been CEO of Reaction Biology and Strongbridge Biopharma, and also has held leadership roles at companies including Johnson & Johnson, Eli Lilly, ImClone and Pfizer. The company on Friday cited Johnson's turnaround experience in naming him to the position.

"His experience leading pre-commercial businesses, deep knowledge of rare diseases and the commercialization process, along with his commitment to culture, are deeply aligned with Applied Therapeutics' priorities," said Teena Lerner, Applied Therapeutics' lead independent director.

Shendelman founded and led the company for the last eight years, during which the company completed several successful clinical trials, built commercial infrastructure and advanced the company's Aldose Reductase Inhibitor franchise across multiple disease areas.

Funtleyder, age 55, will continue to serve as CFO while taking on the interim CEO role.

Write to Paul Ziobro at paul.ziobro@wsj.com

(END) Dow Jones Newswires

December 20, 2024 07:35 ET (12:35 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2492417688"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2492417688\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2492417688?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-20 20:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2492417688","market":"sg","top_or_hot":-1,"title":"Applied Therapeutics CEO Shendelman Steps Down","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Paul Ziobro \n</p>\n<p>\n  Applied <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Chief Executive Shoshana Shendelman is stepping down from the biopharmaceutical company, which named finance chief Les Funtleyder as interim CEO. \n</p>\n<p>\n  Applied Therapeutics also brought in industry veteran John Johnson as executive chairman. Johnson, age 66, has been CEO of Reaction Biology and Strongbridge Biopharma, and also has held leadership roles at companies including Johnson &amp; Johnson, Eli Lilly, ImClone and Pfizer. The company on Friday cited Johnson's turnaround experience in naming him to the position. \n</p>\n<p>\n  \"His experience leading pre-commercial businesses, deep knowledge of rare diseases and the commercialization process, along with his commitment to culture, are deeply aligned with Applied Therapeutics' priorities,\" said Teena Lerner, Applied Therapeutics' lead independent director. \n</p>\n<p>\n  Shendelman founded and led the company for the last eight years, during which the company completed several successful clinical trials, built commercial infrastructure and advanced the company's Aldose Reductase Inhibitor franchise across multiple disease areas. \n</p>\n<p>\n  Funtleyder, age 55, will continue to serve as CFO while taking on the interim CEO role. \n</p>\n<p>\n  Write to Paul Ziobro at paul.ziobro@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 20, 2024 07:35 ET (12:35 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Applied Therapeutics CEO Shendelman Steps Down</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nApplied Therapeutics CEO Shendelman Steps Down\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2024-12-20 20:35</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Paul Ziobro \n</p>\n<p>\n  Applied <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Chief Executive Shoshana Shendelman is stepping down from the biopharmaceutical company, which named finance chief Les Funtleyder as interim CEO. \n</p>\n<p>\n  Applied Therapeutics also brought in industry veteran John Johnson as executive chairman. Johnson, age 66, has been CEO of Reaction Biology and Strongbridge Biopharma, and also has held leadership roles at companies including Johnson &amp; Johnson, Eli Lilly, ImClone and Pfizer. The company on Friday cited Johnson's turnaround experience in naming him to the position. \n</p>\n<p>\n  \"His experience leading pre-commercial businesses, deep knowledge of rare diseases and the commercialization process, along with his commitment to culture, are deeply aligned with Applied Therapeutics' priorities,\" said Teena Lerner, Applied Therapeutics' lead independent director. \n</p>\n<p>\n  Shendelman founded and led the company for the last eight years, during which the company completed several successful clinical trials, built commercial infrastructure and advanced the company's Aldose Reductase Inhibitor franchise across multiple disease areas. \n</p>\n<p>\n  Funtleyder, age 55, will continue to serve as CFO while taking on the interim CEO role. \n</p>\n<p>\n  Write to Paul Ziobro at paul.ziobro@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 20, 2024 07:35 ET (12:35 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LENZ","symbol_name":"Therapeutics","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2492417688","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2492417688","pubTimestamp":1734698100,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Applied Therapeutics Chief Executive Shoshana Shendelman is stepping down from the biopharmaceutical company, which named finance chief Les Funtleyder as interim CEO.Applied Therapeutics also brought in industry veteran John Johnson as executive chairman. Johnson, age 66, has been CEO of Reaction Biology and Strongbridge Biopharma, and also has held leadership roles at companies including Johnson & Johnson, Eli Lilly, ImClone and Pfizer. The company on Friday cited Johnson's turnaround experience in naming him to the position.\"His experience leading pre-commercial businesses, deep knowledge of rare diseases and the commercialization process, along with his commitment to culture, are deeply aligned with Applied Therapeutics' priorities,\" said Teena Lerner, Applied Therapeutics' lead independent director.Shendelman founded and led the company for the last eight years, during which the company completed several successful clinical trials, built commercial infrastructure and advanced the c","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"LENZ":"Therapeutics","APLT":"Applied Therapeutics Inc."},"translate_title":"应用治疗公司首席执行官申德尔曼辞职","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"APLT":0.9,"LENZ":1},"content_text":"By Paul Ziobro \n\n\n  Applied Therapeutics Chief Executive Shoshana Shendelman is stepping down from the biopharmaceutical company, which named finance chief Les Funtleyder as interim CEO. \n\n\n  Applied Therapeutics also brought in industry veteran John Johnson as executive chairman. Johnson, age 66, has been CEO of Reaction Biology and Strongbridge Biopharma, and also has held leadership roles at companies including Johnson & Johnson, Eli Lilly, ImClone and Pfizer. The company on Friday cited Johnson's turnaround experience in naming him to the position. \n\n\n  \"His experience leading pre-commercial businesses, deep knowledge of rare diseases and the commercialization process, along with his commitment to culture, are deeply aligned with Applied Therapeutics' priorities,\" said Teena Lerner, Applied Therapeutics' lead independent director. \n\n\n  Shendelman founded and led the company for the last eight years, during which the company completed several successful clinical trials, built commercial infrastructure and advanced the company's Aldose Reductase Inhibitor franchise across multiple disease areas. \n\n\n  Funtleyder, age 55, will continue to serve as CFO while taking on the interim CEO role. \n\n\n  Write to Paul Ziobro at paul.ziobro@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 20, 2024 07:35 ET (12:35 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"executive","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}